• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by OPKO Health Inc. (Amendment)

    2/9/23 11:27:47 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OPK alert in real time by email
    SC 13G/A 1 tv01588-opkohealthinc.htm SCHEDULE 13G/A opkohealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  OPKO Health Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  68375N103

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  68375N103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    321,219

    7.  SOLE DISPOSITIVE POWER

    40,364,167

    8.  SHARED DISPOSITIVE POWER

    756,327

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    41,120,494

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.32%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    OPKO Health Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    4400 Biscayne Boulevard
    Miami, FL 33137

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    68375N103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $OPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPK

    DatePrice TargetRatingAnalyst
    4/29/2026Outperform → Mkt Perform
    Barrington Research
    11/20/2025Neutral
    Analyst
    10/31/2025$1.60Buy → Hold
    Jefferies
    4/25/2025Neutral
    Analyst
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    12/15/2022$3.00Buy
    H.C. Wainwright
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies

    Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models  Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ:OPK), will announce preclinical data demonstrating the in vivo generation of CAR-T cells and deep systemic B-cell depletion achieved with its MDX3001 candidate in animal models. The data, generated using ModeX's CD3xCD28 antibody-conjugated lipid nanoparticle (LNP)/mRNA platform, will be presented at the ASGCT 2026 Annual Meeting, being held May 11-15 in Bo

    5/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

    MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is approved in Macau, and the companies expect regulatory approvals in China and related territories in 2027. In June 2021, EirGen and Nicoya entered into an agreement for the development and commercialization in Greater China of RAYALDEE® for the treatment of secondary hyperparath

    4/30/26 8:30:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform

    ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference DirectTM, a new digital health platform designed to give consumers direct access to high-quality laboratory testing. Leveraging 45 years of laboratory testing expertise, along with an established footprint of patient service centers across New York and New Jersey, BioReference is expanding its capabilities to deliver a seamless, end-to-end digital experience. BioReference Direct enables individuals to select from a menu of available laboratory tests online, all supported b

    4/30/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    SEC Filings

    View All

    SEC Form DEFA14A filed by OPKO Health Inc.

    DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)

    5/15/26 4:38:03 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by OPKO Health Inc.

    DEFA14A - OPKO HEALTH, INC. (0000944809) (Filer)

    4/30/26 4:03:22 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by OPKO Health Inc.

    DEF 14A - OPKO HEALTH, INC. (0000944809) (Filer)

    4/30/26 4:01:43 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Paganelli John A

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:25:05 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Uppaluri Subbarao V

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:16:55 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Uppaluri Subbarao V

    3 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:10:17 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opko Health downgraded by Barrington Research

    Barrington Research downgraded Opko Health from Outperform to Mkt Perform

    4/29/26 7:41:04 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders. Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025. Additionally, the Company's board appointed C

    9/15/22 4:05:00 PM ET
    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services

    OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx

    MIAMI, June 22, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO's BioReference Laboratories. Ms. Stueland joins GeneDx from Invitae Corporation (NYSE:NVTA), where she served most recently as Chief Commercial Officer, establishing the corporate brand as Invitae evolved from a private company to a public entity with a market capitalization exceeding $6 billion.  "We're thrilled to have Katherine lead the team at GeneDx, which has served clinicians and patients for more than two decades with novel and differentiated technologies for di

    6/22/21 8:00:00 AM ET
    $OPK
    $NVTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $OPK
    Financials

    Live finance-specific insights

    View All

    OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

    MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers

    4/28/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

    MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    4/21/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care